Clinical Scorecard: IL-17, IL-23 Therapies Lead Psoriasis Care
At a Glance
| Category | Detail |
|---|---|
| Condition | Moderate to severe plaque psoriasis |
| Key Mechanisms | Biologic therapies targeting IL-17 and IL-23 pathways |
| Target Population | Patients with moderate to severe plaque psoriasis |
| Care Setting | Clinical settings involving systemic pharmacologic treatments |
Key Highlights
- IL-17 inhibitors ranked highest for efficacy in achieving PASI 90.
- All systemic therapies outperformed placebo in PASI 90 response.
- Serious adverse events were similar across treatments and infrequent.
- Bimekizumab showed the highest certainty of evidence for efficacy.
- Oral therapies had lower PASI 90 response rates compared to biologics.
Guideline-Based Recommendations
Diagnosis
- Assess severity of psoriasis using the Psoriasis Area and Severity Index (PASI).
Management
- Consider IL-17 and IL-23 inhibitors as first-line biologic therapies.
Monitoring & Follow-up
- Monitor for serious adverse events during treatment.
Risks
- Infusion requirements may limit the use of some biologics like infliximab.
Patient & Prescribing Data
Patients with moderate to severe plaque psoriasis, including those with comorbidities or access barriers.
Biologics are preferred for short-term skin clearance; oral therapies remain options for certain patients.
Clinical Best Practices
- Utilize IL-17 and IL-23 inhibitors for effective short-term management.
- Evaluate patient preferences and comorbidities when selecting treatment.
References
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
